

Crash Course IMI2 – What is it? 25 September 2014 - Budapest

Magali Poinot, Legal Manager






Objectives and operations



The way in which pharmaceutical companies develop new medicines is changing







Sci Transl Med 29 January 2014: Vol. 6, Issue 221, p. 221ed2 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3008294

EDITORIAL

DRUG DISCOVERY Turning the Titanic Elias A. Zerhouni

> "Deciphering the complexity of human diseases and finding safe, cost-effective solutions that help people live healthier lives requires collaboration across scientific and medical communities throughout the health care ecosystem.

> Indeed, we must acknowledge that **no single institution**, **company, university, country, or government has a monopoly on innovation.**"





novative Medicines Initi

Innovative Medicines Initiative: Europe's partnership for health



IMI 1 programme

- 2008-2013
- €2 bn budget
- 11 Calls for proposals
- 50+ projects

IMI 2 programme

- 2014-2024
- **Bigger budget**
- More ambitious
- More open





m

From topic definition to project start



STAGE 1 Topic **STAGE 2 Negotiation** definition phase phase **Hospitals** Applicant Academic SMEs consortium research teams **EFPIA EFPIA** Patients' consortium Innovative Medicines Initiative consortium organisations Regulatory authorities Preparation of **Full Project** Identification Submission of Expressions **Proposal** Signature of of topic and of Interest by applicant 8 Project willingness to consortia **Evaluation by** Agreement collaborate by & independent and Grant **EFPIA Evaluation by independent** experts/ethical Agreement companies experts panel Invitation to Start of the selected team Call negotiation \rightarrow to merge with Launch phase **EFPIA** team



A neutral broker:

- To implement programmes and activities in the common interest of all stakeholders
- > To monitor the use of public funds and industry investment
- To guarantee fair and reasonable conditions for optimal knowledge exploitation and dissemination
- To facilitate the interaction between stakeholders, including Intellectual Property agreements
- > To actively **communicate** and promote IMI and its activities





Achievements



The IMI community



Calls 1-8 46 projects > 6000 researchers

61% of projects reported some form of PATIENT INVOLVEMENT

REGULATORS ON BOARD OF

12 PROJECTS


50% of projects have REGULATORY AUTHORITIES

representatives in Scientific Advisory Boards



The IMI portfolio



















Collaboration delivers excellence











Making a difference



Implementation of project results inside industry

Project	Area	Results description
IMIDIA	diabetes	The human beta cell line EndoC BetaH1 has been validated by Endocells and 3 pharma partners confirming their initial insulin secretion capacity. These cells have been successfully transferred as a research tool for drug discovery to industrial partners.
DDMORE	knowledge management	Several drug/disease models identified by DDMORE are adopted or further developed inside the industry.
eTRIKS	knowledge management	Adoption of the eTRIKS results, TransMART system deployments in 5 pharmaceutical companies.
EUROPAIN	Chronic pain	Preclinical model of spontaneous pain in rodents has been developed, standardized, validated, and is already used for internal decision making in the drug development process . The ultraviolet B (UVB) pain model has also started to be used for in house R&D .





Impact on regulatory framework



Innovative Medicines Initiative

Project	Area	Results description	
PROactive	COPD	Qualification Advice completed at the EMA	
EU-AIMS	autism	Started EMA formal scientific advice procedure for qualification of 5 biomarkers in ASD	
еТОХ	drug safety	Provided an update on the eTOX database and the prediction system to the CHMP Safety Working Party (SWP) at EMA. Scientific Advice Procedure was initiated.	
MARCAR	cancer	Has developed new biomarkers, technologies, and alternative test systems that help explain or predict animal and/or human carcinogenic pathways and mechanisms for non-genotoxic carcinogenesis. This will provide enhanced scientific rationale for Carcinogenicity Assessment Document (CAD) submissions, with potential impact for ICH S1 carcinogenicity testing guideline revisions .	
Safe-T	drug safety	Developed and now progressed towards an aligned EMA/FDA qualification a set of novel safety biomarkers for drug-induced kidney, liver, and vascular injury.	
DDMORE	knowledge management	In May 2012 an advisory meeting with EMA and FDA representatives was held. Through a Modelling Review Group , DDMoRe is in regular contact with both the EMA and FDA regarding the qualification of the content of the project's Model Library.	







Total IMI commitment	€ 723 million
Total received by SMEs	€ 133 million
% SME	18.4%
Total IMI participations	886
Total SME participations	135
% SME	15%





SME success stories





SME involved in **SAFE-T** project "Thanks to IMI our company went from **6 to 50 employees.** Now we are ready to go to further expand."



SME involved in IMIDIA project -

"1st product released to the market in 2013 – IMI was instrumental in validation of the first cell line product, 2nd product release planned this year, 3rd diagnostic product in development.

In preparation: **a new patent filing** to protect technologies for the creation of third generation human beta cell lines.



SME involved in PharmaCog project

"We are developing a blood panel for AD for diagnosis, stratification and companion diagnostics in AD. The Panel was tested on 300 patients in IMI project"



SME involved in **eTOX** project

"We have developed in silico models for predicting toxicity, which were validated by pharmas in eTOX. Now **we have signed a contract with one of the companies to use our models in house**."







✓ IMI makes efforts to enhance **patient centric approach**

- Patient dedicated workshops
- Involving patients at all levels
- Providing forum for discussion
- ✓ IMI best practice examples:

EUPATI U-BIOPRED PROactive








Towards IMI2



The Vision for IMI2 – The right prevention and treatment for the right patient at the right time





Trial and Error vs

Information based treatment decisions



Goals of the IMI2 programme



- Increase the success rate of clinical trials of new medicines & vaccines
- ✓ Speed up the earlier stages of drug development
- Develop new treatments for areas of unmet need
- Develop new biological markers to diagnose diseases and assess treatments
- Improve the drug development process by creating tools to assess the efficacy, safety and quality of medicines




IMI2 focuses on the needs of society



• Antimicrobial resistance

- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines



IMI is evolving – what's new?



Scientific focus

- Stronger focus on needs of patients and society
- Research Agenda aligned with WHO priorities
- Increased emphasis on *improving patient access to innovative medicines* (in addition to medicines development)
- Focus on personalised medicine

Rules & procedures

- More entities eligible for funding
- Simpler funding rules (100% of direct costs for research + 25% flat rate for indirect costs)
- Open for other industries / companies (associated partners)
- Open to projects with other sectors (ICT, diagnostics, imaging, animal health, etc.)
- Simpler reporting procedures



Taking part to IMI activities



Why take part in IMI projects?



- Scientific excellence
- Impact on drug development, regulatory procedures, patients' lives
- Access to expertise of scientists from universities, industry, biotechs, regulators, patient groups...
- New business opportunities
- Under IMI 2 improved funding rates
- Flexible intellectual property policy protects partners while promoting use of knowledge



How to take part in IMI projects



Apply for funding

- Look out for new IMI Calls
 - o www.imi.europa.eu
 - o IMI newsletter
 - o Twitter, LinkedIn
- Link up with other experts
- Read and understand the Call documents
 - Info sessions / webinars
 - Contact the IMI Programme Office
- Submit your proposal

Contribute to IMI as an Associated Partner

Your contribution is matched by the EU

- Read the IMI Strategic Research Agenda
- Identify points that match your priorities
- Contact the IMI Programme Office





Translational approaches to disease modifying therapy of type 1 diabetes mellitus (T1DM) Magda.Gunn@imi.europa.eu

Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy

Nathalie.Seigneuret@imi.europa.eu

Submission date: 12 November 2014



Participating to IMI evaluations



Innovative Medicines Initiative **RESEARCH & INNOVATION** European Participant Portal Commission European Commission > Research & Innovation > Participant Portal > Experts Q LOGIN REGISTER Search PP FUNDING OPPORTUNITIES EXPERTS SUPPORT -HOME HOW TO PARTICIPATE H2020 ONLINE MANUAL **Experts** News Join the database of independent experts for European research and innovation. H2020 call for expression for interest for experts (11/2013) The European Commission appoints independent experts to assist with research New calls for expression of and innovation assignments including the evaluation of proposals, monitoring of interest for individual experts projects, and evaluation of programmes, and design of policy. and for organisations to suggest experts were just New experts published in OJ C342 of 22 November 2013, European Who can be an expert? What do expert assignments involve? Commission will soon need experts to evaluate first


Register at: http://ec.europa.eu/research/participants/portal/desktop/en/experts/

Send us an email with your CV at: infodesk@imi.europa.eu



IMI's drug discovery platforms







Thank you

